全文获取类型
收费全文 | 2927篇 |
免费 | 162篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 117篇 |
妇产科学 | 112篇 |
基础医学 | 442篇 |
口腔科学 | 50篇 |
临床医学 | 200篇 |
内科学 | 696篇 |
皮肤病学 | 68篇 |
神经病学 | 456篇 |
特种医学 | 80篇 |
外科学 | 246篇 |
综合类 | 10篇 |
预防医学 | 95篇 |
眼科学 | 13篇 |
药学 | 252篇 |
中国医学 | 2篇 |
肿瘤学 | 252篇 |
出版年
2023年 | 20篇 |
2022年 | 37篇 |
2021年 | 71篇 |
2020年 | 37篇 |
2019年 | 66篇 |
2018年 | 64篇 |
2017年 | 55篇 |
2016年 | 83篇 |
2015年 | 66篇 |
2014年 | 86篇 |
2013年 | 106篇 |
2012年 | 193篇 |
2011年 | 225篇 |
2010年 | 133篇 |
2009年 | 129篇 |
2008年 | 186篇 |
2007年 | 212篇 |
2006年 | 205篇 |
2005年 | 179篇 |
2004年 | 173篇 |
2003年 | 145篇 |
2002年 | 146篇 |
2001年 | 62篇 |
2000年 | 50篇 |
1999年 | 39篇 |
1998年 | 26篇 |
1997年 | 31篇 |
1996年 | 22篇 |
1995年 | 21篇 |
1994年 | 24篇 |
1993年 | 22篇 |
1992年 | 19篇 |
1991年 | 25篇 |
1990年 | 13篇 |
1989年 | 18篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 10篇 |
1985年 | 18篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1976年 | 4篇 |
1975年 | 5篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有3098条查询结果,搜索用时 31 毫秒
111.
112.
113.
Fabrizio Vernieri Nicoletta Brunelli Roberta Messina Carmelina Maria Costa Bruno Colombo Paola Torelli Simone Quintana Sabina Cevoli Valentina Favoni Florindo dOnofrio Gabriella Egeo Renata Rao Massimo Filippi Piero Barbanti Claudia Altamura 《The journal of headache and pain》2021,22(1)
BackgroundMonoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM) and chronic migraine (CM) patients.MethodsThis observational longitudinal cohort study was conducted at 10 Italian headache centres. Consecutive adult patients were followed-up for three months (F-UP1–3) after discontinuation of a one-year erenumab/galcanezumab treatment. The primary endpoint was the change in F-UP MMDs. Secondary endpoints included variation in pain intensity (Numerical Rating Scale, NRS), monthly acute medication intake (MAMI), and HIT-6 scores. We also assessed from F-UP1 to 3 the ≥50% response rate, relapse rate to CM, and recurrence of Medication Overuse (MO).ResultsWe enrolled 154 patients (72.1% female, 48.2 ± 11.1 years, 107 CM, 47 HFEM); 91 were treated with erenumab, 63 with galcanezumab. From F-UP1 to F-UP3, MMDs, MAMI, NRS, and HIT-6 progressively increased but were still lower at F-UP3 than baseline (Friedman’s analysis of rank, p < .001). In the F-UP1–3 visits, ≥50% response rate frequency did not differ significantly between CM and HFEM patients. However, the median reduction in response rate at F-UP3 was higher in HFEM (− 47.7% [25th, − 79.5; 75th,-17.0]) than in CM patients (− 25.5% [25th, − 47.1; 75th, − 3.3]; Mann-Whitney U test; p = .032). Of the 84 baseline CM patients who had reverted to episodic migraine, 28 (33.3%) relapsed to CM at F-UP1, 35 (41.7%) at F-UP2, 39 (46.4%) at F-UP3. Of the 64 baseline patients suffering of medication overuse headache ceasing MO, 15 (18.3%) relapsed to MO at F-UP1, 26 (31.6%) at F-UP2, and 30 (42.3%, 11 missing data) at F-UP3. Lower MMDs, MAMI, NRS, and HIT-6 and higher response rate in the last month of therapy characterized patients with ≥50% response rate at F-UP1 and F-UP3 (Mann-Whitney U test; consistently p < .01).ConclusionMigraine frequency and disability gradually increased after mAbs anti-CGRP interruption. Most patients did not relapse to MO or CM despite the increase in MMDs. Our data suggest to reconsider mAbs anti-CGRP discontinuation. 相似文献
114.
Nicoletta Bernardini PhD Nevena Skroza MD Ersilia Tolino MD Alessandra Mambrin MD Alessia Anzalone MD Veronica Balduzzi MD Daniela Colapietra MD Anna Marchesiello MD Simone Michelini MD Ilaria Proietti PhD Concetta Potenza MD 《International journal of dermatology》2020,59(4):406-411
Recent data support the theory of the involvement of IL-17 in the pathogenesis of several chronic inflammatory skin diseases (psoriasis, atopic dermatitis, acne, hidradenitis suppurativa) and autoimmune skin diseases (alopecia areata, vitiligo, bullous diseases). Even if the role of IL-17 in inflammatory and autoimmune diseases has been reported extensively, its role in tumor is still controversial. Some reports show that Th17 cells eradicate tumors, while others reveal that they promote the initiation and early growth of tumors. Herein, we review the role of IL-17 in the involvement of some common dermatologic diseases: psoriasis, atopic dermatitis, hidradenitis suppurativa, acne, vitiligo, melanoma, and nonmelanoma skin cancers. 相似文献
115.
Gelibter Stefano Genchi Angela Callea Marcella Anzalone Nicoletta Galantucci Sebastiano Volonté Maria Antonietta Filippi Massimo 《Journal of neurology》2020,267(11):3418-3420
Journal of Neurology - 相似文献
116.
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey
下载免费PDF全文
![点击此处可从《Dermatologic therapy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Maria C. Potenza Ketty Peris Enzo Berardesca Luca Bianchi Antonio Richetta Nicoletta Bernardini Clara De Simone Miriam Teoli Arianna Zangrilli Sara D'epiro Diego Orsini Alessandra Narcisi Sergio Chimenti Antonio Costanzo 《Dermatologic therapy》2018,31(1)
This Italian multicenter retrospective study compared the drug survival and efficacy of different anti‐TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression. 1,235 patients were included, 577 with PsO and 658 with PsA. Highest survival rates were observed with adalimumab followed by etanercept and infliximab in PsO and PsA patients. The probability of maintaining PASI response was significantly higher for adalimumab followed by infliximab. For PsO patients, the odds of losing PASI 75 was higher in etanercept‐treated patients (OR: 8.1; 95% CI: 4.2–15.6, p < .001) or infliximab (OR: 6.6; 95% CI: 2.6–16.3, p < .001) vs. adalimumab. Likewise, for PsA patients the odds of losing PASI 75 was higher in etanercept‐treated patients (OR: 2.3; 95% CI: 1.4–3.8, p = .01) or infliximab (OR: 2.2; 95% CI: 1.1–4.1, p = .018) vs. adalimumab. Adalimumab could be the best therapeutic option over other anti‐TNF agents for the treatment of PsO and PsA patients. 相似文献
117.
Michelangelo Mancuso Daniele Orsucci Corrado Angelini Enrico Bertini Valerio Carelli Giacomo Pietro Comi Maria Alice Donati Antonio Federico Carlo Minetti Maurizio Moggio Tiziana Mongini Filippo Maria Santorelli Serenella Servidei Paola Tonin Antonio Toscano Claudio Bruno Luca Bello Elena Caldarazzo Ienco Elena Cardaioli Michela Catteruccia Paola Da Pozzo Massimiliano Filosto Costanza Lamperti Isabella Moroni Olimpia Musumeci Elena Pegoraro Dario Ronchi Donato Sauchelli Mauro Scarpelli Monica Sciacco Maria Lucia Valentino Liliana Vercelli Massimo Zeviani Gabriele Siciliano 《Journal of neurology》2015,262(5):1301-1309
118.
Chlorpromazine protection against interleukin-1 and tumor necrosis factor-mediated activities in vivo. 总被引:2,自引:0,他引:2
R Bertini M Mengozzi M Bianchi J D Sipe P Ghezzi 《International journal of immunopharmacology》1991,13(8):1085-1090
Interleukin (IL-1) and tumor necrosis factor (TNF) are thought to play a key role in septic shock and inflammation. We had previously shown that chlorpromazine (CPZ) has a protective effect in various models of endotoxic shock and IL-1 toxicity. We have tested the effect of CPZ on several activities of IL-1 in vivo. CPZ (4 mg/kg) inhibited increases in serum corticosterone, triglycerides and serum amyloid A (SAA). Chlorpromazine also antagonized these same effects when they were induced by endotoxin or TNF, suggesting that this activity could be implicated in the protective effect of CPZ in various models of endotoxic shock and IL-1 lethality. 相似文献
119.
Cardiac resynchronization therapy: variations in echo-guided optimized atrioventricular and interventricular delays during follow-up 总被引:1,自引:0,他引:1
Valzania C Biffi M Martignani C Diemberger I Bertini M Ziacchi M Bacchi L Rocchi G Rapezzi C Branzi A Boriani G 《Echocardiography (Mount Kisco, N.Y.)》2007,24(9):933-939
BACKGROUND: Relatively few data are available on long-term echocardiographic optimization of atrioventricular (AV) and interventricular (VV) delay programming in cardiac resynchronization therapy (CRT). We assessed variations in optimized AV and VV delays during long-term follow-up. METHODS: Thirty-seven consecutive heart failure patients received Doppler echocardiographic optimization of AV and VV delay within 48 hours from CRT device implantation, at 6 months and at 12 months (the last for the first enrolled 14 patients). RESULTS: After implantation, median optimized AV delay was 100 ms (range, 45 ms); VV optimization led to simultaneous biventricular activation in 4 patients, left ventricular preactivation in 17 patients and right ventricular preactivation in 16 patients. At 12 months median AV delay decreased to 85 ms (23 ms) (P < 0.05 vs. baseline). With respect to previous assessment, VV delay variations > or =40 ms were observed in 41% of the patients at 6 months and in 57% of the tested patients at 12 months. A nonconcordance (by Kappa test) of optimized VV delays was found between each new assessment and the previous one. VV delay optimization was associated with significant (P < 0.001) increases in aortic velocity time integral both at baseline and during follow-up. CONCLUSIONS: Echocardiographic optimization of AV and VV delay is associated with broad intraindividual variability during follow-up. A new assessment of optimized VV delays during long-term follow-up reveals a nonconcordance with previous values and provides increases in forward stroke volume. 相似文献